Login
$GENB
$10.60 +$0.11 (1.05%) After hours

$GENB SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year

12 Nov 2026 10-Q
05 Nov 2026 SCHEDULE 13G
04 Nov 2026 Form 4: Arnold Frances, Director

Sold 11,409 shares ($185K)

29 Oct 2026 144
03 Sep 2026 Form 4: Arnold Frances, Director

Sold 1,000 shares ($16K)

02 Sep 2026 144
01 Sep 2026 144
26 Aug 2026 8-K: Regulation FD Disclosure

GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients. Dave Singh1, Kapil Mayawala2, Victoria Szenes2, Andreas Eich3, Brian Lea...

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions

15 May 2026 SCHEDULE 13G
15 May 2026 SCHEDULE 13G
07 May 2026 10-Q
07 May 2026 8-K: Results of Operations and Financial Condition

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance

12 Mar 2026 Form 3: Pioneering Medicines 02, Llc, 10% owner

Holds 1,562,500 shares of Common Stock

06 Mar 2026 Form 4: Nally Michael, Director

Bought 20,000 shares ($240K)

02 Mar 2026 Form 4: Vessey Rupert, Director

Granted 29,561 Stock Option (Right to Buy)

02 Mar 2026 Form 4: Arnold Frances, Director

Granted 29,561 Stock Option (Right to Buy)

02 Mar 2026 Form 4: Martin Sean, Chief Legal Officer & GC

Granted 190,034 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support